High Efficacy of a Single Oral Dose of Ondansetron 8 mg Versus a Metoclopramide Regimen in the Prevention of Acute Emesis Induced by Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Chemotherapy for Breast Cancer

REFERENCES

• French Epirubicin Study Group. A prospective ran-domised phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J C1M Oncol 1988; 6: 679-88.
   Google Scholar
• Cubeddu LX, Hoffman IS, Fuenmayor NT, Finn A. Antagonism of serotonin S3 receptors with ondansetron pre-vents nausea and emesis induced by cyclophosphamide-con-taMing chemotherapy regimens. J Clin Oncol 1990; 8: 1721–7.
   PubMed Web of Science ®Google Scholar
• Beck TM, Ciociola AA, Jones SE et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiv-ing cyclophosphamide-based chemotherapy. Ann Intern Med 1993; 118: 407–13.
   Google Scholar
• Cubeddu LX, Pendergrass K, Ryan T et al. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Am J C1M Oncol 1994; 17: 137–46.
   Google Scholar
• Di Benedetto J, Cubeddu LX, Ryan T et al. Ondansetron for nausea and vomiting associated with moder-ately emetogenic cancer chemotherapy. C1M Therapeut 1995; 17: 1091–8.
   Google Scholar
• Martin Jimenez M, Diaz-Rubio E, Blazquez Encinar JC et al. Tolerancia, toxicidad y aceptation del tratamiento quimioterapico adyuvante FAG (5-fluorouracilo, adriamicina y ciclofosfamida) en el cancer de mama. Analisis de 100 enfer-mas consecutivas. Neoplasia 1988; 5: 8–14.
   Google Scholar
• Bonneterre J, Chevalier B, Metz R et al. A randomized double blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J C1M Oncol 1990; 8: 1063–9.
   Google Scholar
• Kaasa S, Kvaloy S, Dicato MA et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer 1990; 26: 311–4.
   Google Scholar
• Marschner NW, Adler M, Nagel GA, Christmann D, Fenzl E, Upadhyaya. Double blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclo-pramide in advanced breast cancer patients treated with epiru-bicin and cyclophosphamide. Eur J Cancer 1991; 27: 1137–40.
   Google Scholar
• Seynaeve C, Schuller J, Buser K et al. Comparison of the antiemetic efficacy of ondansetron given as either a con-tinuous infusion or a single intravenous dose, in acute cis-platin-induced emesis. A multicentre, double-blind, random-ized, parallel group study. Br J Cancer 1992; 66: 192–7.
   Google Scholar
• Ruff P, Paska W, Goedhals L et al. Ondansetron com-pared with granisetron in the prophylaxis of cisplatin-induced acute emesis: A multicentre double-blind, randomised, parallel-group study. Oncology 1994; 51: 113–8.
   Google Scholar
• The Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexam-ethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995; 6: 805–10.
   Google Scholar
• Jantunen IT, Muhonen TT, Kataja VV, Flander MK, Teerenhovi L. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic therapy - a randomised study. Eur J Cancer 1993; 29A: 1669–72.
   PubMed Web of Science ®Google Scholar
• Dicato M. Oral treatment with ondansetron in the out-patient setting. Eur J Cancer 1991; 27 (suppl 1): S18-9.
   Google Scholar
• Davidson NGP, Hughes LS. Oral ondansetron adminis-tered either as a single daily or twice daily dose in the preven-tion of nausea and vomiting induced by moderately emeto-genic chemotherapy (Abstr.) Ann Oncol 1994; 5 (suppl 8): 212.
   Google Scholar
• Kaizer L, Warr D, Hoskins P et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12: 1050–7.
   Google Scholar
• Beck TM, Hesketh PJ, Madajewicz S et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992; 10: 1969–75.
   Google Scholar
• Gandara DR, Roila F, Warr D, Edelman MJ, Perez EA, Gralla RJ. Consensus proposal for 5TH3 antagonist in the prevention of acute emesis related to highly emetogenic chemotherapy (dose, schedule, and route of administration). Support Care Cancer 1998; 6: 237–43.
   PubMed Web of Science ®Google Scholar
• Steward A, McQuade B, Cronje JDE et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicen-tre, double-blind, double-dummy, randomised, parallel group study. Oncology 1995; 52: 202–10.
   Google Scholar
• Bosnjak SM, Neskovic-Konstantinovic ZB, Jovanovic-Micic DJ, Mitrovic LB, Radulovic SS. Single 8 mg dose of oral ondansetron failed to prevent FAG chemotherapy - induced acute nausea and vomiting. J Chemother 1996; 4: 315–318.
   Google Scholar
• The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1–5.
   Google Scholar
• Razavi D, Delvaux N, Farvacques C et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 1993; 11: 1384-90.
   Google Scholar
• Tonato M, Roila F, Del Favero A, Ballatori E. Methodology of trials with antiemetics. Support Care Cancer 1996; 4: 281–6.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103–9.
   Google Scholar
• Aranda E, Guillem V, Carrato A et al. Higher risk of emesis induced by cyclophosphamide combinations containing anthracyclines (Abstr.) Ann Oncol 1998 ; 4 (suppl 4): 146.
   Google Scholar
• Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy and radiotherapy - induced emesis: Results of the Perugia consensus conference. Ann Oncol 1998; 9: 811–9.
   Google Scholar
• Gralla RJ, Osoba D, Kris MG et al for the American Society of Clinical Oncology. Recommendations for the use of antiemetics: evidence-based, clinical practice guideliness. J Clin Oncol 1999; 17: 2971-94.
   Google Scholar
• Campora E, Guidici S, Merlini L et al. Ondansetron and dexamethasone versus standard combination antiemetic therapy. Am J Clin Oncol (CCT) 1994; 17: 522–6.
   Google Scholar
• Jantunen IT, Kataja VV, Muhonen TT. An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 1997; 33: 66–74.
   PubMed Web of Science ®Google Scholar
• Lindley CJ, McCune S, Goodin M, Cane TP, Abang A, Socinski MA. Efficacy of oral ondansetron and dexamethasone in prevention of nausea and vomiting associated with moder-ately-high and highly emetogenic chemotherapy (Abstr.) J Clin Oncol 1998; 17:63a.
   Google Scholar
• The Italian group for Antiemetic Research. Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients? Ann Oncol 1997; 8: 561–7.
   Google Scholar
• Herrstedt J, Aapro MS, Smyth JF, Del Favero A. Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 1998; 6: 204–14.
   PubMed Web of Science ®Google Scholar